tetano
Editor, Senior Moderator
Published ahead of print 11 September 2013, doi: 10.1128/JVI.01388-13 J. Virol. November 2013 vol. 87 no. 22 12471-12480
Antibody Recognition of the Pandemic H1N1 Influenza Virus Hemagglutinin Receptor Binding Site
Minsun Honga*,
Peter S. Leea,b,
Ryan M. B. Hoffmana,
Xueyong Zhua,
Jens C. Krausec,
Nick S. Laursena,
Sung-il Yoona*,
Langzhou Songe,
Lynda Tusseye,
James E. Crowe Jr.c,d,
Andrew B. Warda and
Ian A. Wilsona,b
+ Author Affiliations
Department of Integrative Structural and Computational Biologya
The Skaggs Institute for Chemical Biology,b The Scripps Research Institute, La Jolla, California, USA
Departments of Pediatricsc
Microbiology and Immunology,d Vanderbilt University Medical Center, Nashville, Tennessee, USA.
VaxInnate Corporation, Cranbury, New Jersey, USAe
ABSTRACT
Influenza virus is a global health concern due to its unpredictable pandemic potential. This potential threat was realized in 2009 when an H1N1 virus emerged that resembled the 1918 virus in antigenicity but fortunately was not nearly as deadly. 5J8 is a human antibody that potently neutralizes a broad spectrum of H1N1 viruses, including the 1918 and 2009 pandemic viruses. Here, we present the crystal structure of 5J8 Fab in complex with a bacterially expressed and refolded globular head domain from the hemagglutinin (HA) of the A/California/07/2009 (H1N1) pandemic virus. 5J8 recognizes a conserved epitope in and around the receptor binding site (RBS), and its HCDR3 closely mimics interactions of the sialic acid receptor. Electron microscopy (EM) reconstructions of 5J8 Fab in complex with an HA trimer from a 1986 H1 strain and with an engineered stabilized HA trimer from the 2009 H1 pandemic virus showed a similar mode of binding. As for other characterized RBS-targeted antibodies, 5J8 uses avidity to extend its breadth and affinity against divergent H1 strains. 5J8 selectively interacts with HA insertion residue 133a, which is conserved in pandemic H1 strains and has precluded binding of other RBS-targeted antibodies. Thus, the RBS of divergent HAs is targeted by 5J8 and adds to the growing arsenal of common recognition motifs for design of therapeutics and vaccines. Moreover, consistent with previous studies, the bacterially expressed H1 HA properly refolds, retaining its antigenic structure, and presents a low-cost and rapid alternative for engineering and manufacturing candidate flu vaccines.
http://jvi.asm.org/content/87/22/12471.short?rss=1
Antibody Recognition of the Pandemic H1N1 Influenza Virus Hemagglutinin Receptor Binding Site
Minsun Honga*,
Peter S. Leea,b,
Ryan M. B. Hoffmana,
Xueyong Zhua,
Jens C. Krausec,
Nick S. Laursena,
Sung-il Yoona*,
Langzhou Songe,
Lynda Tusseye,
James E. Crowe Jr.c,d,
Andrew B. Warda and
Ian A. Wilsona,b
+ Author Affiliations
Department of Integrative Structural and Computational Biologya
The Skaggs Institute for Chemical Biology,b The Scripps Research Institute, La Jolla, California, USA
Departments of Pediatricsc
Microbiology and Immunology,d Vanderbilt University Medical Center, Nashville, Tennessee, USA.
VaxInnate Corporation, Cranbury, New Jersey, USAe
ABSTRACT
Influenza virus is a global health concern due to its unpredictable pandemic potential. This potential threat was realized in 2009 when an H1N1 virus emerged that resembled the 1918 virus in antigenicity but fortunately was not nearly as deadly. 5J8 is a human antibody that potently neutralizes a broad spectrum of H1N1 viruses, including the 1918 and 2009 pandemic viruses. Here, we present the crystal structure of 5J8 Fab in complex with a bacterially expressed and refolded globular head domain from the hemagglutinin (HA) of the A/California/07/2009 (H1N1) pandemic virus. 5J8 recognizes a conserved epitope in and around the receptor binding site (RBS), and its HCDR3 closely mimics interactions of the sialic acid receptor. Electron microscopy (EM) reconstructions of 5J8 Fab in complex with an HA trimer from a 1986 H1 strain and with an engineered stabilized HA trimer from the 2009 H1 pandemic virus showed a similar mode of binding. As for other characterized RBS-targeted antibodies, 5J8 uses avidity to extend its breadth and affinity against divergent H1 strains. 5J8 selectively interacts with HA insertion residue 133a, which is conserved in pandemic H1 strains and has precluded binding of other RBS-targeted antibodies. Thus, the RBS of divergent HAs is targeted by 5J8 and adds to the growing arsenal of common recognition motifs for design of therapeutics and vaccines. Moreover, consistent with previous studies, the bacterially expressed H1 HA properly refolds, retaining its antigenic structure, and presents a low-cost and rapid alternative for engineering and manufacturing candidate flu vaccines.
http://jvi.asm.org/content/87/22/12471.short?rss=1